Concepedia

Author

Huyang Xie

Fudan University Shanghai Cancer CenterORCID

Also Known As

H. Xie, Hu-Yang Xie, Huyang Xie

73

Publications

1K

Citations

15

H-Index

23

Concepts

All Affiliations

Fudan University Shanghai Cancer CenterShanghai Medical College of Fudan UniversityFudan UniversityShanghai Jiao Tong UniversityRuijin Hospital
HX

About

Huyang Xie is an author at Fudan University Shanghai Cancer Center specializing in medicine, tumor biology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

320

2

Pathology

3

3

124

3

Immunology

2

2

231

4

Cell Biology

1

1

38

5

Surgical Oncology

1

1

51

Huyang Xie

×

17

Publications

1K

Citations

15

H-Index

YearCitations

Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer

Hangcheng Fu, Yu Zhu, Yiwei Wang,

Clinical Cancer Research

2018

197

Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion

Qiang Fu, Le Xu, Yiwei Wang,

European Urology

2018

196

Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao, Zihao Qi, Yangyang Pang,

Cancer Research

2019

152

Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer

Zheng Liu, Yu Zhu, Le Xu,

OncoImmunology

2018

75

Tumor Infiltrating Mast Cells (TIMs) Confers a Marked Survival Advantage in Nonmetastatic Clear-Cell Renal Cell Carcinoma

Hangcheng Fu, Yu Zhu, Yiwei Wang,

Annals of Surgical Oncology

2016

51

The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma

Fujiang Xu, Kun Chang, Jian Ma,

Scientific Reports

2017

42

MiR-455-5p Suppresses the Progression of Prostate Cancer by Targeting CCR5

Qianwei Xing, Huyang Xie, Bingye Zhu,

BioMed Research International

2019

40

CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma

Zewei Wang, Huyang Xie, Lin Zhou,

Oncotarget

2016

38

circLPAR1 is a novel biomarker of prognosis for muscle‑invasive bladder cancer with invasion and metastasis by miR‑762

Guowen Lin, Haoyue Sheng, Huyang Xie,

Oncology Letters

2019

38

Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma

Frank V. Fossella, John McCann, Anthony W. Tolcher,

Journal of Clinical Oncology

2005

35

Page 1